International regulatory status and reimbursement recommendations of haematological malignancy drugs withdrawn from the FDA accelerated approval pathway.
- DOI
- 10.1016/j.jcpo.2026.100825
- Published
- 2026 Oct 23
- Container
- Journal of cancer policy
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.jcpo.2026.100825,
title = {International regulatory status and reimbursement recommendations of haematological malignancy drugs withdrawn from the FDA accelerated approval pathway.},
author = {Mulsant SS and Kesselheim AS and Naci H},
year = {2026},
journal = {Journal of cancer policy},
doi = {10.1016/j.jcpo.2026.100825},
url = {https://doi.org/10.1016/j.jcpo.2026.100825}
}RIS
TY - JOUR TI - International regulatory status and reimbursement recommendations of haematological malignancy drugs withdrawn from the FDA accelerated approval pathway. AU - Mulsant SS AU - Kesselheim AS AU - Naci H PY - 2026 JO - Journal of cancer policy DO - 10.1016/j.jcpo.2026.100825 UR - https://doi.org/10.1016/j.jcpo.2026.100825 ER -
APA
SS, M., AS, K., & H, N. (2026). International regulatory status and reimbursement recommendations of haematological malignancy drugs withdrawn from the FDA accelerated approval pathway.. Journal of cancer policy. https://doi.org/10.1016/j.jcpo.2026.100825
Source records
- pubmed · retrieved 2026-11-10T14:50:25.710Z